TLDR
- Eli Lilly stock jumps 3.75% after $7.8B Centessa acquisition deal
- Centessa deal adds orexin sleep therapies to Lilly’s pipeline
- Lilly offers $47 per share including milestone-based payments
- Orexin drugs target narcolepsy and broader neurological disorders
- Lilly expands neuroscience focus amid rising market competition
Eli Lilly and Company (LLY) stock climbed to $919.87, gaining 3.75% after a strong session. The move followed a $7.8 billion acquisition agreement with Centessa Pharmaceuticals. The deal expands Lilly’s neuroscience pipeline and strengthens its position in sleep disorder treatments.
Acquisition Structure and Strategic Expansion
Eli Lilly agreed to acquire Centessa for an upfront cash payment of $38 per share. This values Centessa at about $6.3 billion based on its recent closing price. The offer includes contingent value rights worth up to $9 per share.
The total consideration could reach $47 per share if development milestones are achieved. Consequently, the full deal value may rise to approximately $7.8 billion. The transaction remains subject to regulatory approval and is expected to close in the third quarter.
Lilly shares reacted positively after the announcement and maintained gains throughout the session. Centessa’s ADR surged sharply following the premium offer. The strong response reflects confidence in the strategic fit and future pipeline potential.
Orexin Pipeline and Neuroscience Focus
The acquisition centers on Centessa’s orexin receptor agonist programs targeting excessive daytime sleepiness. These treatments focus on conditions such as narcolepsy and idiopathic hypersomnia. Such disorders affect daily functioning by impairing wakefulness.
Centessa’s lead drug candidate, cleminorexton, has shown strong results in mid-stage clinical trials. The compound targets the brain’s sleep-wake cycle through orexin receptor activation. Another candidate, ORX142, supports broader neurological applications.
These therapies belong to a growing drug class gaining traction across the pharmaceutical industry. Orexin-based approaches may extend to Alzheimer’s disease and depression. This potential supports Lilly’s expansion into complex neurological conditions.
Competitive Position and Broader Growth Strategy
The orexin drug segment is expected to see increasing competition in the near term. A competing treatment from Takeda Pharmaceutical Company is currently under regulatory review. Approval could arrive later this year, setting early market benchmarks.
Centessa’s lead therapy may reach approval around 2028 based on analyst projections. Despite the timeline, early data suggests strong differentiation within the class. Market estimates place orexin therapies between $15 billion and $20 billion in potential value.
Lilly continues to reinvest revenue from its diabetes and obesity portfolio into new areas. Products such as Zepbound and Mounjaro have driven strong cash generation. The company has accelerated acquisitions to expand its long-term pipeline.
Earlier deals include planned acquisitions of Orna Therapeutics and Ventyx Biosciences. These moves signal a consistent strategy focused on innovation and diversification. With the Centessa agreement, Lilly deepens its neuroscience footprint while strengthening future growth pathways.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
